Maria Aguirre, MD
Radiation Oncology · Munster, INNPI 1710205067
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,000 of the $2,514 with a category attached, or 79.6%. Davol Inc. accounts for 79.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2021 at $2,214 and has fallen 98.7% since, to $29 in 2025.
Across 12 payments — averaging $209.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Davol Inc.$2K
- Myriad Genetic Laboratories, Inc.$120
- E.r. Squibb & Sons, L.L.C.$120
- Regeneron Healthcare Solutions, Inc.$94
- AstraZeneca$30
- Novartis$29
- plus $120 from 5 others
What the payments were for
- Speaking & faculty fees$2,00080%
- Food & beverage$51420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Davol Inc. | 1 | $2,000 |
| Myriad Genetic Laboratories, Inc. | 1 | $120 |
| E.r. Squibb & Sons, L.L.C. | 1 | $120 |
| Regeneron Healthcare Solutions, Inc. | 1 | $94 |
| AstraZeneca | 1 | $30 |
| Novartis | 1 | $29 |
| Tactile Systems Technology Inc | 2 | $28 |
| Bayer | 1 | $26 |
| Siemens Medical Solutions USA, Inc. | 1 | $25 |
| Stryker | 1 | $24 |
| Myovant Sciences Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,514 in reported general payments places this provider in the 85th percentile of 116 radiation oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $859 |
| Lidocaine Hcl ViscousLidocaine Hcl | 15 | $357 |
| Tamsulosin Hcl | 27 | $210 |
| Pentoxifylline | 12 | $174 |
| Cyclobenzaprine Hcl | 13 | $6 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Munster
- Neil SeifMunster$921
- Virag DandekarMunster$660
- Brian ChangFort Wayne$13K
- Michael EatonIndianapolis$11K
- William PorterMadison$8K
- Binh TranMishawaka$7K
- Gordon WatsonIndianapolis$6K
- John CoxIndianapolis$5K
- Houman VaghefiGoshen$5K
- Peter GarrettIndianapolis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.